clinical trial · NCT02944487
A Study to Assess the Safety and Pharmacokinetics of Lucerastat (OGT 923) in Healthy Subjects
Healthy SubjectsLucerastatPlacebo
brief summary
The objectives of this study were to evaluate the safety and tolerability of lucerastat, and to determine its pharmacokinetic profile as single oral doses at different strengths.
started
Oct 1, 2002
primary completion
Dec 1, 2002
completion
Dec 1, 2002
last updated
May 1, 2025
detailed description
The subjects were enrolled sequentially to five dose groups, starting with the lowest dose level. Subjects could participate in only one Group.
official title
A Randomised, Double-blind, Placebo-controlled Ascending Dose Tolerance Study of OGT 923 in Healthy Male Volunteers
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol